LONDON (AFX) - Biopharmaceutical company SR Pharma PLC said it will proceed with a full, 28-da
y toxicological evaluation of its RNAi product candidate Atu027 before starting clinical testing later this year.
The company said the announcement follows the successful completion of further toxicology studies of Atu027, which it hopes to develop as a cancer treatment.
'The positive results from these toxicology studies is another important step forward in the development of Atu027 for systemic cancer indications and keeps us on track to start clinical testing in mid-2007,' chairman Iain Ross said.
COPYRIGHT Copyright AFX News Limited 2006. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.